Business, energy, technology, markets and global industry news from Business News Today

Myqorzo

PharmaDeviceNews Myqorzo
Representative image: Cardiac imaging and hypertrophic cardiomyopathy assessment as Cytokinetics reports positive Phase 3 ACACIA-HCM results for aficamten, supporting a planned FDA filing in symptomatic non-obstructive HCM.
Pharma & Biotech

Aficamten clears pivotal Phase 3 test in non-obstructive HCM as Cytokinetics prepares FDA filing

Aficamten hits both Phase 3 ACACIA-HCM endpoints as Cytokinetics prepares an FDA filing. See what the results mean for Myqorzo growth.

Read More
Pharma & Biotech

Edgewise Therapeutics’ Phase 2 HCM data put systolic function into sharper focus

Find out how Edgewise Therapeutics’ EDG-7500 data could reshape HCM drug development as Phase 3 questions emerge.

Read More